Merck to seek emergency authorization for oral Covid treatment

Merck to seek emergency authorization for oral Covid treatment after ‘compelling results’ in trials

 

KEY POINTS

• A phase 3 trial of Merck and Ridgeback Biotherapeutics’ oral antiviral treatment molnupiravir showed it reduced the risk of hospitalization or death by around 50% in Covid-19 patients.
• Merck plans to seek Emergency Use Authorization in the U.S. and submit marketing applications to other global drug regulators.
• If authorized by regulatory bodies, molnupiravir could be the first oral antiviral medicine for Covid-19.

https://www.cnbc.com/2021/10/01/merck-to-seek-emergency-authorization-for-oral-covid-19-treatment.html

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/

https://www.wenxuecity.com/news/2021/10/01/10946654.html

所有跟帖： 

• 疫苗能力有穷时，疫苗安全尚未全，药物开发及时雨，老药新用是必然 -枫林晓- ♂ (110 bytes) () 10/01/2021 postreply 05:11:03

• 对照组有8例死亡而用药组没死亡，效果真的不错，默克开盘前股票暴涨8% -走顺路- ♂ (0 bytes) () 10/01/2021 postreply 05:51:46

• 50%有效,不知FDA会不会批准？ -5181- ♂ (0 bytes) () 10/01/2021 postreply 05:54:58

• 要是三期临床最终表现还是这样，而且没有骇人听闻的副作用，肯定会批复。成为战胜新冠的利器 -fuz- ♂ (0 bytes) () 10/01/2021 postreply 06:59:08

• 默克原文，使用Molnupiravir三期临试的进展报告：可以减少一半轻、中症患者转重或死亡。这是迄今为止，效果最好的口服治疗药 -fuz- ♂ (5514 bytes) () 10/01/2021 postreply 06:34:12

• 优点：1.效果似乎不受基础病的影响；2. 与变异株无关；3. 有巨大的生产潜力，可以快速推广应用 -fuz- ♂ (0 bytes) () 10/01/2021 postreply 06:56:19

• 大厂宣传就是牛，到现在，媒体上一片正面期待。安全问题可能很大，没人敢说？ -枫林晓- ♂ (0 bytes) () 10/01/2021 postreply 07:01:17

• 有， -fuz- ♂ (4505 bytes) () 10/01/2021 postreply 07:37:13

• 好。总算有一处存留。你看到meidia宣传里有写这些问题的吗？ -枫林晓- ♂ (0 bytes) () 10/01/2021 postreply 08:19:54